Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Multicentre, Open-label, Dose Escalation Study to Determine the Safety and Preliminary Efficacy of MBS8(1V270) Administered Intravenously to Cancer Patients With Advanced Solid Tumours

NCT04855435 is registered in ClinicalTrials.gov with MonTa Biosciences ApS as lead sponsor.

NCT NCT04855435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04855435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Multicentre, Open-label, Dose Escalation Study to Determine the Safety and Preliminary Efficacy of MBS8(1V270) Administered Intravenously to Cancer Patients With Advanced Solid Tumours
Lead sponsor
MonTa Biosciences ApS
Phase
Phase 1
Overall status
Recruiting
Start date
April 12, 2021
Completion date
June 30, 2027
Enrollment
106 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, cutaneous melanoma, uveal melanoma, metastatic